Navigation Links
Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
Date:8/6/2014

NEW YORK, Aug. 6, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a Nevada corporation (the "Company"), a clinical-stage company developing novel therapies for the treatment of chronic pain is pleased to announce that Financial Industry Regulatory Authority (FINRA) has approved the Company's application for a name change from Camp Nine, Inc. to Relmada Therapeutics, Inc. and assigned a new trading symbol, RLMD.

The Company also received a new CUSIP number, 75955J105 for its common stock.  This change was made in conjunction with the Company's filing of a Certificate of Amendment to its Articles of Incorporation, on July 8, 2014, changing the Company's name from Camp Nine, Inc. to Relmada Therapeutics, Inc.  The former ticker symbol of the Company was CMPE.  The effective date for these changes is today August 6, 2014.  

"Management is extremely pleased to announce our new name and trading symbol," said Sergio Traversa, CEO of Relmada Therapeutics Inc.  "We are confident that this will help the investors to better identify us with our strategic focus, which is to serve as a market leader in the successful development of innovative products that address the treatment of pain.  With the public listing process now complete, the Company can now focus its efforts on the development, advancement and commercialization of our four programs in various stages of clinical trials."

Relmada is currently developing LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine and MepiGel, its FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine.

About Relmada Therapeutics Inc.

Relmada Therapeutics is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at different stages of development and a deep early stage pipeline.  The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisory board.  The Company's approach is expected to reduce overall clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.

Forward-Looking Statements

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements.  The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected.  Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.  Visit our website at, www.relmada.com

 


'/>"/>
SOURCE Relmada Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
2. Relmada Therapeutics Announces LevoCap ER Development Progress
3. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
4. Advinus Therapeutics, a TATA Enterprise, Meets Year 1 Milestone in Drug Discovery Alliance
5. Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
6. Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics
7. Boston Therapeutics, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
8. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
9. Dual Chamber Syringes & Injectors. Devices, Therapeutics, Markets and Forecasts
10. Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics
11. Inhibikase Therapeutics, Inc. Elects Anthony Zook To The Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)...  The particle counters market is projected to ... 275.9 million in 2016, at a CAGR of ... http://www.reportlinker.com/p04718602-summary/view-report.html The growing pharmaceutical and ... growth in manufacturing industries in emerging nations are ... counters. On the other hand, technical limitations of ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top five ... art competition. Selected from 15 submissions from around the nation, the top five finalists ... iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the competition ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The Radiology ... excellence in radiology marketing programs at the annual Building Better Radiology Marketing Programs ... Fort Worth Hotel in Fort Worth, Texas. Nine awards are given out in five ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations ... International Elite division on February 12th. Ms. Esparza qualified into this prestigious ... qualifier competition held in Las Vegas, Nevada. Frida is one of approximately 25 ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the ... The Jensie Gran Fondo of Marin. For the second year in a row, ... mineral-based sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... The 89th ... the winner of the 2016 National Education Policy Center Bunkum Award. We invite you ... in 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), ...
Breaking Medicine News(10 mins):